Evidence map›Paper›PMID 32615654›Full record

ArticleThe Korean journal of internal medicine2021

Long-term efficacy of vasodilating β-blocker in patients with acute myocardial infarction: nationwide multicenter prospective registry.

Jaehoon Chung, Jung-Kyu Han, Han-Mo Yang, Kyung-Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Myung Ho Jeong, Hyo-Soo Kim, investigators for Korea Acute Myocardial Infarction Registry (KAMIR)

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Calcium and Heart Failure: How Did We Get Here and Where Are We Going?International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jaehoon ChungDivision of Cardiology, Department of Internal Medicine, National Medical Center, Seoul, Korea.
Jung-Kyu HanCardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Han-Mo YangCardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Kyung-Woo ParkCardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Hyun-Jae KangCardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Bon-Kwon KooCardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Myung Ho JeongDepartment of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea.
Hyo-Soo KimCardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
investigators for Korea Acute Myocardial Infarction Registry (KAMIR)
Seoul National University Hospital · KRChonnam National University Hospital · KRNational Medical Center · KR

Funding

Research of Korea Centers for Disease Control and Prevention 2016-ER6304-02
6 · The paper itself

Abstract

BACKGROUND/

aimsLong-term benefit of vasodilating β-blockers is unknown. This study aimed to investigate the long-term benefit of vasodilating β-blockers over conventional β-blockers in patients with acute myocardial infarction (AMI).

methodsUsing nationwide prospective multicenter Korean Acute Myocardial Infarction Registry data, we analyzed 3-year clinical outcomes of 7,269 patients with AMI who received percutaneous coronary intervention (PCI) and β-blocker therapy. Patients were classified according to treatment strategy (vasodilating β-blockers vs. conventional β-blockers). The primary endpoint was a composite of cardiac death, myocardial infarction (MI), and hospitalization for heart failure (HF) at 3 years. Secondary outcomes were each component of the primary outcome. Propensity score matching was performed to adjust for differences of baseline characteristics.

resultsIn 3,079 pairs (6,158 patients) of propensity score-matched patients, the primary outcome occurred significantly less in the vasodilating β-blockers group compared with the conventional β-blockers group (7.6% vs. 9.8%, p = 0.003). Among the secondary outcomes, cardiac death occurred significantly less in the vasodilating β-blockers group than in the conventional group (3.5% vs. 4.8%, p = 0.015). The incidence rates of MI (2.4% vs. 3.0%, p = 0.160) or hospitalization for HF (2.6% vs. 3.2%, p = 0.192) were not significantly different between the two groups.

conclusionVasodilating β-blocker therapy was associated with better clinical outcomes compared with conventional β-blocker therapy in AMI patients undergoing PCI during 3 years follow-up. Vasodilating β-blockers could be recommended preferentially for these patients.

Indexed as

Myocardial InfarctionPercutaneous Coronary InterventionAdrenergic beta-AntagonistsHumansNeoplasm Recurrence, LocalRegistriesTreatment OutcomeAdrenergic beta-AntagonistsBeta-blockerCoronary artery diseaseMyocardial infarctionPercutaneous coronary intervention

Identifiers

PMID32615654
PMCPMC8009151
OpenAlexW3040683788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.